Aurora Signs Letter of Intent with Cangenx Biotech Inc.

CSE: ACB

VANCOUVER, Feb. 10, 2015 /CNW/ - Aurora Cannabis Inc. (CSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce that its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc. ("Aurora"), has signed a Letter of Intent to negotiate a potential contract with CanGenX BioTech Inc. ("CanGenX"). Aurora is an applicant to become a licensed producer pursuant to the Marihuana for Medical Purposes Regulations ("MMPR").

The Letter of Intent allows Aurora to move forward in its plans to establish an in-house plant tissue culture program. Once our starting materials are received in accordance with our application, plant tissue culture will be employed as the starting point for our production batches which assures healthy, disease-free plants along with the capacity to consistently meet facility requirements and to scale production to meet the current market requirement for stable, characterized plants. As far as the company is aware, Aurora is the only company in Canada to utilize plant tissue culture, to begin, as the production standard. Plant Tissue Culture will allow for a more rapid, efficient full crop cycle turn-over than traditional methods. Additionally, our plant tissue culture and microbiology laboratory provides the basis for genetic analysis along with future, patentable breeding programs carried out under the direction of our Science Advisors.

Aurora will be collaborating on this project in our facility with Geoff White, CEO and founder of CanGenX. Mr. White has over 10 years of hands on experience in the agri-tech industry along with over a decade of experience in the field of molecular biology and plant tissue culture, including research into hemp production. Mr. White's educational accomplishments include two Bachelor of Science degrees comprised of a major in Biology and a minor in Chemistry and a degree in Agriculture with honours in Plant Science. To support his science background, Mr. White has proven managerial skills backed with entrepreneurial success. CanGenX works in a newly built, state-of-the-art laboratory located in Penticton, British Columbia. We also welcome Mr. White as a key member of our Science Advisory Team.

With proven success in the creation of custom, strain-specific tissue culture protocols along with the incorporation of advanced monitoring and production technologies, Mr. White is committed to working with Aurora to achieve its goals of employing cutting edge science for the advancement of safe, pure, high quality medical cannabis production. Mr. White comments, "Tissue culture micro-propagation will allow Aurora to maintain the highest quality standard of uniform, disease free starter plants to introduce into their production system. This will result in the cleanest possible plants for the production of pharmaceutical grade products under the MMPR."

On behalf of the Board of Directors,
AURORA CANNABIS INC.

Terry Booth
CEO

Caution Regarding Forward-Looking Information:

Certain statements in this press release constitute "forward looking" statements within the meaning of applicable Canadian securities legislation, which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. When used in this press release, such statements may use such words as "may," "will," "expect," "believe," "plan" and other similar terminology. These statements include, but are not limited to, the expectation that Aurora will negotiate and settle the terms of the proposed contract and consummate the proposed contract generally upon the terms as currently contemplated. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this press release. The forward looking statements involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, delays with the negotiation of the terms of the proposed contract or delays or failure to satisfy the conditions to completion of the proposed contract, the execution of a formal agreement, regulatory requirements and other customary conditions. The Company undertakes no obligation to update publicly or revise any forward looking information, whether a result of new information, future results or otherwise, except as required by law.

The CSE, securities commission or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.

SOURCE Aurora Cannabis Inc.

Please contact the Company at: Telephone: [phone], Facsimile: [phone]